Vianney Tricou | Senior Director, Medical & Scientific Affairs
Takeda Pharmaceuticals International AG
Dr. Vianney Tricou is a clinical development and medical affairs professional with expertise in infectious diseases. Holding a PharmD from the University of Lyon and a PhD from the University of Oxford, he has gained extensive experience working in Asia and Africa with leading academic institutions. Since 2014, Dr. Tricou has been part of Takeda's Vaccine Business Unit, where he has contributed to the development and commercialization of TAK-003/Qdenga, a tetravalent dengue vaccine candidate. Based in Zurich, Switzerland, he currently holds the position of Senior Director of Medical & Scientific Affairs. Dr. Tricou has authored over 40 peer-reviewed articles in his field.
Appearances:
Main Congress Day 1 - 22nd April @ 12:25
Keynote panel: The emergence and re-emergence of dengue and its unprecedented worldwide spread
- Effect of climate change on spread
- Data on circulating serotypes
- Introduction of new vaccine in high-risk areas
- Strengthening surveillance systems in affected countries
- View on vaccine recommendations
- Global epidemiology and what increases in Americas have meant to US
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events